Table 1.
Characteristics of the subjects included
| Age (years) | Gender | Final state | Baseline liver disease | HBV-DNA level (IU/mL) | TBIL (μmol/L) | INR | ALT (U/L) | AST (U/L) | AST/ALT | ALB (G/L) | GLB (G/L) | A/G | CREA (μmol/L) | MELD score | PaO2/FiO2(mmHg) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 42 | Male | Survive | Cirrhosis | 3.54 × 107 | 231.9 | 1.7 | 1174 | 519 | 0.44 | 30.7 | 27.4 | 1.12 | 54 | 17.5 | 433 |
| Case 2 | 39 | Male | Survive | Cirrhosis | 2.43 × 106 | 251.2 | 2.2 | 101 | 105 | 1.04 | 31.8 | 32.3 | 0.98 | 54 | 20.7 | 452 |
| Case 3 | 46 | Female | Survive | Cirrhosis | 1.65 × 105 | 211.1 | 1.6 | 65 | 106 | 1.63 | 32.5 | 43.6 | 0.75 | 79 | 20.1 | 428 |
| Case 4 | 52 | Female | Death | Cirrhosis | 2.27 × 106 | 406.2 | 3.0 | 74 | 130 | 1.76 | 29.5 | 24.6 | 1.2 | 55 | 26.2 | 463 |
| Case 5 | 41 | Male | Death | Cirrhosis | 1.83 × 105 | 372.8 | 4.5 | 26 | 60 | 2.37 | 34.9 | 21.8 | 1.6 | 145 | 39.7 | 198 |
| Case 6 | 40 | Male | Death | Cirrhosis | 2.18 × 105 | 255.8 | 3.3 | 30 | 23 | 0.77 | 45.5 | 31.5 | 1.44 | 79 | 29.0 | 477 |
| Healthy control 1 | 45 | Female | – | – | – | 8.0 | 0.9 | 37 | 32 | 0.86 | 43 | 25 | 1.72 | 59 | – | – |
| Healthy control 2 | 47 | Male | – | – | – | 7.9 | 0.8 | 27 | 25 | 0.93 | 52 | 32 | 1.63 | 62 | – | – |
| Healthy control 3 | 43 | Male | – | – | – | 9.2 | 1.0 | 32 | 28 | 0.88 | 46 | 34 | 1.35 | 64 | – | – |
TBIL total bilirubin (normal range: 5–21 μmol/L), INR international normalized ratio (normal range: 0.8–1.2), CREA creatinine (normal range: 57–97 μmol/L), ALT Alanine aminotransferase (normal range: 9–50 U/L), AST Aspartate aminotransferase (normal range: 15–40 U/L), AST/ALT DeRitis ratio(normal range: 0.8–1.5), ALB Albumin (normal range: 40–55 g/L), GLB Globulin (normal range: 20 ~ 40 g/L), A/G Albumin globulin ratio (normal range: 1.2–2.4), MELD Model for end-stage liver disease, HBV-DNA level (normal range: < 100 IU/mL), PaO2/FiO2 a ratio of PaO2 of arterial oxygen to FiO2 (normal range: 400–500 mmHg)